This report is a preliminary assessment of global investments in research and development
(R&D) devoted to the discovery and development of new therapies and treatment strategies
for HIV. As part of a broader effort to track and analyze HIV/AIDS spending, UNAIDS
commissioned the Treatment Action Group (TAG) and AVAC to measure global R&D spending
for HIV treatment, starting with the year 2009.
From a total of 144 surveyed institutions, 48 funders reported investing $2.5 billion in HIV
treatment R&D in 2009. The scope of HIV treatment R&D included HIV basic science, drug
discovery, drug development, diagnostics, and operational and implementation science on
Time to act: Save a million lives by 2015 - Prevent and treat tuberculosis among people living with HIV
We live in a time of unprecedented hope for the 33.3 million people living with HIV worldwide. Antiretroviral therapy (ART) offers the promise of a full and fulfilling life. Now people living with HIV can raise their families, work and pursue their dreams. But a thief is in our midst—one that is routinely robbing people, and the countries they live in, of their futures. Every minute, three people living with HIV have their lives snatched away by tuberculosis (TB). Africa, hit hard by HIV, is also hit hard by TB. TB is the main cause of death in people living with HIV.
The primary goals of Positive Health, Dignity and Prevention are to improve the dignity, quality, and length of life of people living with HIV; which, if achieved will, in turn, have a beneficial impact on their partners, families, and communities, including reducing the likelihood of new infections.
Many countries with a high burden of HIV infection also face burgeoning epidemics of noncommunicable diseases. Similar to HIV, noncommunicable diseases are most frequent in low- and middle-income countries, and the age-adjusted death rates from noncommunicable diseases are nearly twice as high in low- and middle-income countries as in high-income countries. People living with HIV often also have high rates of noncommunicable diseases. With HIV programmes rapidly expanding, people with HIV are living longer and ageing, and are developing non-HIV-related chronic conditions similar to the rest of the population.
In Namibia, HIV-positive women are being tricked into sterilisation. Is this a country desperate to curb Aids, or just a blatant human rights violation? Marion Stevens of the Women and HIV/AIDS Gauge, Health Systems Trust, came across this recent article, which exposes the reality of what’s happening in Namibia’s state hospitals.
Barker PM, Venter F. Setting district-based annual targets for HAART and PMTCT - a first step in planning effective intervention for the HIV/AIDS epidemic. S Afr Med J. 2007 Oct;97(10):916-7.
This report presents the methods and findings of a qualitative study of the experiences of patients taking medication for HIV infection as part of an antiretroviral therapy (ART) programme in five sites in KwaZulu-Natal (KZN), South Africa. The study, known as the ADHERE Project, was designed by MEASURE Evaluation and implemented in collaboration with Health Systems Trust to provide information to the KwaZulu-Natal Department of Health for use in expanding and improving their ART services.